Search

Your search keyword '"CTI Van Wijk"' showing total 81 results

Search Constraints

Start Over You searched for: Author "CTI Van Wijk" Remove constraint Author: "CTI Van Wijk"
81 results on '"CTI Van Wijk"'

Search Results

1. Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation

2. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy

3. Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile

4. Clinical and translational attributes of immune-related adverse events

5. IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval

6. Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis

8. JAK Inhibition with Baricitinib for Severe CVID-Related Enteropathy: a Case Report

9. Compartment-driven imprinting of intestinal CD4 T cells in inflammatory bowel disease and homeostasis

10. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance

11. Limited excretion of dupilumab into breastmilk: A case report

12. Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

13. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

14. Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab

15. Biomarkers in atopic dermatitis

16. High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease

17. Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies

18. Bi-allelic variants in NAE1 cause intellectual disability, ischiopubic hypoplasia, stress-mediated lymphopenia and neurodegeneration

19. Compartmentalization and persistence of dominant (regulatory) T cell clones indicates antigen skewing in juvenile idiopathic arthritis

20. New Insights via RNA Profiling of Formalin-Fixed Paraffin-Embedded Lung Tissue of Pulmonary Fibrosis Patients

21. Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition

22. Conventional dendritic cells type 1 are strongly enriched, quiescent and relatively tolerogenic in local inflammatory arthritis

23. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients

24. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry

25. Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis: A Prospective Clinical Cohort Study from the BioDay Registry

26. T cell interaction with activated endothelial cells primes for tissue-residency

27. Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint

28. Immune monitoring and treatment in immune-mediated inflammatory diseases

29. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

30. Case Report: Lessons Learned From Subsequent Autologous and Allogeneic Hematopoietic Stem Cell Transplantations in a Pediatric Patient With Relapsing Polychondritis

31. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

32. Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort

33. Unraveling heterogeneity in pediatric atopic dermatitis:: identification of serum biomarker based patient clusters

34. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

35. T-cell subsets in the skin and their role in inflammatory skin disorders

36. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response

37. ZFP36 family members regulate the pro-inflammatory features of psoriatic dermal fibroblasts

38. Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters

39. COMPARTMENTALIZATION, PERSISTENCE AND CONSERVED SHARED MOTIFS OF DOMINANT (REGULATORY) T CELL CLONES IN AUTOIMMUNE INFLAMMATION

40. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

41. Homeostatic function and inflammatory activation of ileal CD8+ tissue-resident T cells is dependent on mucosal location

42. Chronically Activated T-cells Retain Their Inflammatory Properties in Common Variable Immunodeficiency

43. Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

44. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology

45. Antigen-driven PD-1+ TOX+ BHLHE40+ and PD-1+ TOX+ EOMES+ T lymphocytes regulate juvenile idiopathic arthritis in situ

46. Tissue-Resident Memory T Cells in Chronic Inflammation-Local Cells with Systemic Effects?

47. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis

48. Flow cytometric evaluation of the neutrophil compartment in COVID-19 at hospital presentation: A normal response to an abnormal situation

49. Healthy cotwins share gut microbiome signatures with their inflammatory bowel disease twins and unrelated patients

50. Dysregulated RASGRP1 expression through RUNX1 mediated transcription promotes autoimmunity

Catalog

Books, media, physical & digital resources